GoAI
Get started
Noile-Immune Biotech Inc. logo

Noile-Immune Biotech Inc.

4893.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥145

+¥1.00 · +0.69%

Aug 24, 3:30 PM JST

4893.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Established in 2015 and based in Minato, Japan, this company is dedicated to exploring and advancing CAR-T cell technology for use in cancer immunotherapy treatments.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Koji Tamada
Listed since
Jun 28, 2023
Employees
23

Market position

Volume
78.3K
0.5× average
Average volume
155.84K
Average daily volume
Market cap
6.28B JPY
Beta
0.08
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.84B JPY
P/E (TTM)
-8.33×
P/B (TTM)
1.76×
P/S (TTM)
8,781.45×
EV / EBITDA
-2.31×
Earnings yield
-13.78%
Free cash flow yield
0.00%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
-112546.85%
Net margin
-105437.76%
Return on equity
-20.18%
Return on assets
-19.78%
Return on invested capital
-20.25%

Financial health

Debt / equity
0×
Current ratio
53.54×
Altman Z-score
40.13
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1705%-4714%-11132%-17550%Gross margin, FY2021: 77.27%Gross margin, FY2022: 98.87%Gross margin, FY2023: 99.29%Gross margin, FY2024: 97.43%Gross margin, FY2025: 100.00%Operating margin, FY2021: -761.93%Operating margin, FY2022: -16.99%Operating margin, FY2023: -244.74%Operating margin, FY2024: -14092.30%Operating margin, FY2025: -15945.08%Net margin, FY2021: -789.26%Net margin, FY2022: -61.78%Net margin, FY2023: -356.68%Net margin, FY2024: -12711.94%Net margin, FY2025: -15870.72%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 77.27%. Gross margin FY2022 98.87%. Gross margin FY2023 99.29%. Gross margin FY2024 97.43%. Gross margin FY2025 100.00%. Operating margin FY2021 -761.93%. Operating margin FY2022 -16.99%. Operating margin FY2023 -244.74%. Operating margin FY2024 -14092.30%. Operating margin FY2025 -15945.08%. Net margin FY2021 -789.26%. Net margin FY2022 -61.78%. Net margin FY2023 -356.68%. Net margin FY2024 -12711.94%. Net margin FY2025 -15870.72%.

Income trends

Revenue

5M JPY-34.10%

Operating income

−797.25M JPY+25.43%

Net income

−793.54M JPY+17.72%
Income trends across reported periods801.36M JPY99.04M JPY−603.27M JPY−1.31B JPYRevenue, FY2021: 100.73M JPYRevenue, FY2022: 625.78M JPYRevenue, FY2023: 316.82M JPYRevenue, FY2024: 7.59M JPYRevenue, FY2025: 5M JPYOperating income, FY2021: −767.51M JPYOperating income, FY2022: −106.35M JPYOperating income, FY2023: −775.39M JPYOperating income, FY2024: −1.07B JPYOperating income, FY2025: −797.25M JPYNet income, FY2021: −795.04M JPYNet income, FY2022: −386.62M JPYNet income, FY2023: −1.13B JPYNet income, FY2024: −964.46M JPYNet income, FY2025: −793.54M JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 100.73M JPY. Revenue FY2022 625.78M JPY. Revenue FY2023 316.82M JPY. Revenue FY2024 7.59M JPY. Revenue FY2025 5M JPY. Operating income FY2021 −767.51M JPY. Operating income FY2022 −106.35M JPY. Operating income FY2023 −775.39M JPY. Operating income FY2024 −1.07B JPY. Operating income FY2025 −797.25M JPY. Net income FY2021 −795.04M JPY. Net income FY2022 −386.62M JPY. Net income FY2023 −1.13B JPY. Net income FY2024 −964.46M JPY. Net income FY2025 −793.54M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue5M JPY7.59M JPY316.82M JPY625.78M JPY100.73M JPY
Cost of goods sold—195K JPY2.26M JPY7.08M JPY22.9M JPY
Gross profit5M JPY7.39M JPY314.56M JPY618.71M JPY77.83M JPY
Research and development360.88M JPY579.88M JPY646.71M JPY334.8M JPY514.83M JPY
Selling, general, and administrative441.38M JPY496.7M JPY443.25M JPY390.25M JPY330.52M JPY
Operating expenses802.25M JPY1.08B JPY1.09B JPY725.05M JPY845.34M JPY
Interest income6.4M JPY609K JPY44K JPY55K JPY80K JPY
Operating income−797.25M JPY−1.07B JPY−775.39M JPY−106.35M JPY−767.51M JPY
Net income−793.54M JPY−964.46M JPY−1.13B JPY−386.62M JPY−795.04M JPY

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-18.33
FY2025
Latest fiscal-year revenue
5M JPY
FY2025 · -34.10% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-8.13-15.08-22.04-28.99FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend687.86M439.55M191.23M-57.08MFY21FY22FY23FY24FY25

4893.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,987

-0.34%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,797

+0.57%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,895

0.00%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,210

+0.12%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,858

+0.86%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,406.5

+0.82%

Continue in GoAI

Research 4893.T

research.disclaimer